Evidence map›Paper›PMID 39865562›Full record

ArticleFuture oncology (London, England)2025

Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib.

Francesco Passamonti, Siddhi Korgaonkar, Rohan C Parikh, Manoj Chevli, Aylin Yucel, Julien Rombi, Shalon Jones, Dorothy Zissler, Keith L Davis, Samantha Slaff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Myelofibrosis: Treatment Options After Ruxolitinib Failure.Current oncology (Toronto, Ont.) · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Francesco PassamontiUniversità degli Studi di Milano, Milan, Italy.
Siddhi KorgaonkarRTI Health Solutions, Research Triangle Park, NC, USA.
Rohan C ParikhRTI Health Solutions, Research Triangle Park, NC, USA.
Manoj ChevliBristol Myers Squibb, Uxbridge, UK.
Aylin YucelBristol Myers Squibb, Princeton, NJ, USA.
Julien RombiRTI Health Solutions, Lyon, France.
Shalon JonesBristol Myers Squibb, Princeton, NJ, USA.
Dorothy ZisslerBristol Myers Squibb, Princeton, NJ, USA.
Keith L DavisRTI Health Solutions, Research Triangle Park, NC, USA.
Samantha SlaffBristol Myers Squibb, Princeton, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAssess real-world fedratinib (FEDR) treatment patterns and clinical outcomes in patients with primary or secondary myelofibrosis following discontinuation of ruxolitinib (RUX). PATIENTS &

methodsThis study was a retrospective, noninterventional medical record review of patients in Canada, Germany, and the United Kingdom (UK). A total of 70 physicians (primarily hematologist-oncologists [78.6%]) provided data for 196 eligible patients.

resultsPatients were mostly male (62.8%) with primary myelofibrosis (76.5%) and initiated FEDR at a mean age of 67.7 years. Median treatment duration was 11.5 months (median follow-up, 13.8 months), and nearly half (49.5%) of patients initiated FEDR at the label-indicated dose of 400 mg daily. Six months post-initiation, 77.7% and 66.8% of patients experienced symptom and spleen response, respectively. Kaplan-Meier estimates of median progression-free and overall survival from initiation were 23.8 months (95% CI, 21.1-27.6) and 29.8 months (95% CI, 23.9-NE), respectively.

conclusionThese findings demonstrate real-world FEDR effectiveness among patients with myelofibrosis who discontinued RUX.

Indexed as

Practice Patterns, Physicians'Primary MyelofibrosisPyrrolidinesSulfonamidesAgedAged, 80 and overBenzenesulfonamidesCanadaFemaleGermanyHumansMaleMiddle AgedNitrilesPyrazolesPyrimidinesBenzenesulfonamidesfedratinibNitrilesPyrazolesPyrimidinesPyrrolidinesruxolitinibSulfonamidesfedratinibmedical record reviewMyelofibrosisreal-world evidenceruxolitinibsurvival analysis

Identifiers

PMID39865562
PMCPMC11845104

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.